Selected research
Industry Research
Neurofibromatoses Type II Therapecutics Industry Research Report 2026
Market perspective
The global Neurofibromatoses Type II Therapecutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neurofibromatoses Type II Therapecutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neurofibromatoses Type II Therapecutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neurofibromatoses Type II Therapecutics include AstraZeneca Plc, Recursion Pharmaceuticals Inc, Plex Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, Beta Pharma Inc and Arno Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neurofibromatoses Type II Therapecutics market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neurofibromatoses Type II Therapecutics Market by Company
AstraZeneca Plc
Recursion Pharmaceuticals Inc
Plex Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Beta Pharma Inc
Arno Therapeutics Inc
Neurofibromatoses Type II Therapecutics Segment by Type
LB-205
LB-201
Icotinib Hydrochloride
FRAX-597
AR-42
Others
Neurofibromatoses Type II Therapecutics Segment by Application
Clinic
Hospital
Home Care
Neurofibromatoses Type II Therapecutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurofibromatoses Type II Therapecutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurofibromatoses Type II Therapecutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurofibromatoses Type II Therapecutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neurofibromatoses Type II Therapecutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neurofibromatoses Type II Therapecutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neurofibromatoses Type II Therapecutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- LB-205
- LB-201
- Icotinib Hydrochloride
- FRAX-597
- AR-42
- Others
Applications
- Clinic
- Hospital
- Home Care
Companies covered
- AstraZeneca Plc
- Recursion Pharmaceuticals Inc
- Plex Pharmaceuticals Inc
- Lixte Biotechnology Holdings Inc
- Beta Pharma Inc
- Arno Therapeutics Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neurofibromatoses Type II Therapecutics Market Size (2021-2032)
- 2.2.2 Global Neurofibromatoses Type II Therapecutics Sales (2021-2032)
- 2.2.3 Global Neurofibromatoses Type II Therapecutics Market Average Price (2021-2032)
- 2.3 Neurofibromatoses Type II Therapecutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 LB-205
- 2.3.3 LB-201
- 2.3.4 Icotinib Hydrochloride
- 2.3.5 FRAX-597
- 2.3.6 AR-42
- 2.3.7 Others
- 2.4 Neurofibromatoses Type II Therapecutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Home Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neurofibromatoses Type II Therapecutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neurofibromatoses Type II Therapecutics Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Neurofibromatoses Type II Therapecutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Neurofibromatoses Type II Therapecutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Neurofibromatoses Type II Therapecutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neurofibromatoses Type II Therapecutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neurofibromatoses Type II Therapecutics, Product Type & Application
- 3.8 Global Manufacturers of Neurofibromatoses Type II Therapecutics, Established Date
- 3.9 Global Neurofibromatoses Type II Therapecutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca Plc
- 4.1.1 AstraZeneca Plc Company Information
- 4.1.2 AstraZeneca Plc Business Overview
- 4.1.3 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Portfolio
- 4.1.5 AstraZeneca Plc Recent Developments
- 4.2 Recursion Pharmaceuticals Inc
- 4.2.1 Recursion Pharmaceuticals Inc Company Information
- 4.2.2 Recursion Pharmaceuticals Inc Business Overview
- 4.2.3 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
- 4.2.5 Recursion Pharmaceuticals Inc Recent Developments
- 4.3 Plex Pharmaceuticals Inc
- 4.3.1 Plex Pharmaceuticals Inc Company Information
- 4.3.2 Plex Pharmaceuticals Inc Business Overview
- 4.3.3 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
- 4.3.5 Plex Pharmaceuticals Inc Recent Developments
- 4.4 Lixte Biotechnology Holdings Inc
- 4.4.1 Lixte Biotechnology Holdings Inc Company Information
- 4.4.2 Lixte Biotechnology Holdings Inc Business Overview
- 4.4.3 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Portfolio
- 4.4.5 Lixte Biotechnology Holdings Inc Recent Developments
- 4.5 Beta Pharma Inc
- 4.5.1 Beta Pharma Inc Company Information
- 4.5.2 Beta Pharma Inc Business Overview
- 4.5.3 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Portfolio
- 4.5.5 Beta Pharma Inc Recent Developments
- 4.6 Arno Therapeutics Inc
- 4.6.1 Arno Therapeutics Inc Company Information
- 4.6.2 Arno Therapeutics Inc Business Overview
- 4.6.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Portfolio
- 4.6.5 Arno Therapeutics Inc Recent Developments
5 Global Neurofibromatoses Type II Therapecutics Market Scenario by Region
- 5.1 Global Neurofibromatoses Type II Therapecutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neurofibromatoses Type II Therapecutics Sales by Region: 2021-2032
- 5.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Region: 2021-2026
- 5.2.2 Global Neurofibromatoses Type II Therapecutics Sales by Region: 2027-2032
- 5.3 Global Neurofibromatoses Type II Therapecutics Revenue by Region: 2021-2032
- 5.3.1 Global Neurofibromatoses Type II Therapecutics Revenue by Region: 2021-2026
- 5.3.2 Global Neurofibromatoses Type II Therapecutics Revenue by Region: 2027-2032
- 5.4 North America Neurofibromatoses Type II Therapecutics Market Facts & Figures by Country
- 5.4.1 North America Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
- 5.4.3 North America Neurofibromatoses Type II Therapecutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Neurofibromatoses Type II Therapecutics Market Facts & Figures by Country
- 5.5.1 Europe Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
- 5.5.3 Europe Neurofibromatoses Type II Therapecutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Neurofibromatoses Type II Therapecutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neurofibromatoses Type II Therapecutics Market Facts & Figures by Country
- 5.7.1 South America Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
- 5.7.3 South America Neurofibromatoses Type II Therapecutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2032)
- 6.1.1 Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2021-2032)
- 6.2 Global Neurofibromatoses Type II Therapecutics Revenue by Type (2021-2032)
- 6.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Neurofibromatoses Type II Therapecutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2032)
- 7.1.1 Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2021-2032)
- 7.2 Global Neurofibromatoses Type II Therapecutics Revenue by Application (2021-2032)
- 7.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Neurofibromatoses Type II Therapecutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neurofibromatoses Type II Therapecutics Value Chain Analysis
- 8.1.1 Neurofibromatoses Type II Therapecutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neurofibromatoses Type II Therapecutics Production Mode & Process
- 8.2 Neurofibromatoses Type II Therapecutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neurofibromatoses Type II Therapecutics Distributors
- 8.2.3 Neurofibromatoses Type II Therapecutics Customers
9 Global Neurofibromatoses Type II Therapecutics Analyzing Market Dynamics
- 9.1 Neurofibromatoses Type II Therapecutics Industry Trends
- 9.2 Neurofibromatoses Type II Therapecutics Industry Drivers
- 9.3 Neurofibromatoses Type II Therapecutics Industry Opportunities and Challenges
- 9.4 Neurofibromatoses Type II Therapecutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst